A prospective clinical study evaluating the efficacy and safety of all-trans retinoic acid combined with the IDH1 inhibitor ivosidenib in IDH1-mutated MDS (ChiCTR) - Oct 16, 2026 - P4 | N=20 | Not yet recruiting | Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
New P4 trial • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • IDH1
|